SIRT3 and cardiac hypertrophy: Dihydromyricetin ameliorated myocardial hypertrophy and fibrosis in DCM through activation of SIRT3, inhibition of oxidative stress, inflammation, and apoptosis, demonstrating its medical potential in DCM treatment [58].